Gautschi, Mirja; Oberholzer, Patrick Antony; Baumgartner, Marc; Gadaldi, Karolina; Yawalkar, Nikhil; Hunger, Robert (2016). Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study. Journal of the American Academy of Dermatology, 74(1), 81-87.e1. Elsevier 10.1016/j.jaad.2015.08.031
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Hunger 3.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) |
|
|
Text
Lentigo_maligna_Submission_170815.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (113kB) | Preview |
|
|
Text (Table 1)
Table_1m.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (58kB) | Preview |
|
|
Text (Table 2)
Table_2m.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (33kB) | Preview |
|
|
Image (Figure 1)
Figure_1_gross.tif - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (739kB) | Preview |
|
|
Image (Figure 2)
Figure 2 arrows-1.tif - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (2MB) | Preview |
|
|
Image (Figure 3)
Figure_3.tif - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (175kB) | Preview |
|
|
Image (Figure supplementary)
Figure_supplementary_gross.tif - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (307kB) | Preview |
BACKGROUND
More data are needed to define factors that predict long-term success after imiquimod therapy for lentigo maligna (LM).
OBJECTIVE
We sought to determine the demographic, clinical, and histologic prognostic markers of relapse-free survival in patients with LM who were treated with imiquimod.
METHODS
This was a single-arm, open-label, nonrandomized, prospective study.
RESULTS
Eighty-nine patients with histologically confirmed LM and a median follow-up time of 4.8 years after imiquimod treatment were included in our study. Sixteen patients (18%) relapsed. Statistically significant indicators of an increased risk of local recurrence included: the total number of melanocytes, the number of basal and suprabasal melanocytes and the number of pagetoid spreading melanocytes.
LIMITATIONS
Our study was a single-center, nonrandomized study.
CONCLUSION
An assessment of different melanocyte fractions in the diagnostic baseline biopsy specimen may help to predict the response of LM to imiquimod therapy.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Oberholzer, Patrick Antony, Baumgartner, Marc (A), Gadaldi, Karolina, Yawalkar, Nikhil, Hunger, Robert |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0190-9622 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Andrea Studer-Gauch |
Date Deposited: |
09 Mar 2016 10:48 |
Last Modified: |
29 Mar 2023 23:34 |
Publisher DOI: |
10.1016/j.jaad.2015.08.031 |
PubMed ID: |
26601565 |
Uncontrolled Keywords: |
efficacy; follow-up; imiquimod; lentigo maligna; prognostic marker; recurrence; topical immunomodulators |
BORIS DOI: |
10.7892/boris.76277 |
URI: |
https://boris.unibe.ch/id/eprint/76277 |
Actions (login required)
 |
Edit item |